RUNX2 and prostate carcinoma: RUNX1 has been associated with leukemia [8,9] and solid tumor development in the skin, lung, intestine, and breast [9,10], while RUNX2 has been associated with osteosarcoma [11,12], thyroid carcinoma [13], as well as breast and prostate cancers [14].